Men with localized prostate cancer and high-risk biochemical recurrence benefit from treatment with enzalutamide, either alongside leuprolide or alone.

A chart review of the Veterans Affairs health system indicates that there are around 14 cases of prostate cancer per year among transgender women.

The 15-year data from the ProtecT trial show low rates of prostate cancer-specific mortality among men with prostate-specific antigen-detected, localized disease regardless of whether they received active monitoring, prostatectomy, or radiotherapy.

Rezvilutamide significantly delays disease progression and death relative to bicalutamide when each is combined with androgen deprivation therapy in patients with high-volume metastatic, hormone-sensitive prostate cancer, research shows.

Men who receive radiotherapy for localized prostate cancer have a significantly elevated risk for a second primary cancer relative to their counterparts not exposed to radiotherapy, suggests a database analysis.

This independent medical education meeting has been funded by Astellas.

Prostate-specific antigen-based screening can reduce prostate cancer-specific mortality, but there are concerns about overdiagnosis, overtreatment and economic value.

DOI [Teaser] Key Points for Decision Makers Prostate-specific membrane antigen positron emission tomography combined with computed tomography is a new and more accurate method to detect prostate cancer.

The ENACT trial has demonstrated a significantly reduced risk for progression with the use of enzalutamide in men with low- or intermediate-risk localized prostate cancer undergoing active surveillance.

Magnetic resonance imaging-guided focal ultrasound therapy is a feasible treatment for grade group 2–3 prostate cancer, indicate phase 2b trial findings published in The Lancet Oncology .

A meta-analysis has identified a significantly elevated risk for prostate cancer-specific mortality with increases in BMI, waist circumference, and waist-to-hip ratio.

Use of 5α-reductase inhibitors is not associated with an increased risk for prostate cancer mortality, and long-term use may indeed reduce the risk, a Swedish population-based study has found.

Both traditional hormone therapy and novel androgen receptor signaling inhibitors may be associated with neurocognitive impairment in men with prostate cancer, suggests WHO pharmacovigilance data.

Fewer than one in 10 older men initiating androgen deprivation therapy for localized or regional prostate cancer receive dual-energy X-ray absorptiometry screening to assess bone mineral density, US study findings indicate.

Irisin decreases the expression of  MMP2  and  MMP9 , which may be potential cancer markers in the diagnosis of prostate cancer.

medwireNews: The EMA has recommended approval  of relugolix for the treatment of advanced hormone-sensitive prostate cancer.

All-cause mortality is significantly reduced in men with prostate cancer receiving adjuvant versus early salvage radiotherapy, particularly if they have four or more positive pelvic lymph nodes, research suggests.

The CADMUS investigators report a “slightly lower” rate of detection of clinically significant prostate cancers with multiparametric ultrasound than multiparametric MRI, but a higher rate of referrals for biopsy.

Taking nonselective, but not selective, beta blockers at the time of radical prostatectomy may decrease the risk for prostate cancer recurrence, findings indicate.